References
1. Choudhary S, Sreenivasulu K, Mitra P, Misra S, Sharma P. Role of
Genetic Variants and Gene Expression in the Susceptibility and Severity
of COVID-19. Ann Lab Med. 2021;41(2):129-138.
2. Bontempi E. The europe second wave of COVID-19 infection and the
Italy ”strange” situation. Environ Res. 2021;193:110476.
3. Bakhshandeh B, Sorboni SG, Javanmard AR, et al. Variants in ACE2;
potential influences on virus infection and COVID-19 severity.Infect Genet Evol. 2021;90:104773.
4. Zhao S, Lou J, Cao L, et al. Quantifying the transmission advantage
associated with N501Y substitution of SARS-CoV-2 in the United Kingdom:
An early data-driven analysis. J Travel Med. 2021.
5. Yi C, Sun X, Ye J, et al. Key residues of the receptor binding motif
in the spike protein of SARS-CoV-2 that interact with ACE2 and
neutralizing antibodies. Cell Mol Immunol. 2020;17(6):621-630.
6. Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional
properties of SARS-CoV-2 spike protein: potential antivirus drug
development for COVID-19. Acta Pharmacol Sin.2020;41(9):1141-1149.
7. Bachmann MF, Zinkernagel RM. The influence of virus structure on
antibody responses and virus serotype formation. Immunol Today.1996;17(12):553-558.
8. Faria NR, Mellan TA, Whittaker C, et al. Genomics and epidemiology of
a novel SARS-CoV-2 lineage in Manaus, Brazil. medRxiv. 2021.
9. Petersen RL. Strategies Using Bio-Layer Interferometry Biosensor
Technology for Vaccine Research and Development. Biosensors
(Basel). 2017;7(4).
10. Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70
deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.Nat Med. 2021.
11. Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes
neutralization by South African COVID-19 donor plasma. bioRxiv.2021.
12. Greaney AJ, Starr TN, Gilchuk P, et al. Complete Mapping of
Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape
Antibody Recognition. Cell Host Microbe. 2021;29(1):44-57 e49.
13. Andreano E, Piccini G, Licastro D, et al. SARS-CoV-2 escape in vitro
from a highly neutralizing COVID-19 convalescent plasma. bioRxiv.2020.
14. Rathnasinghe R, Jangra S, Cupic A, et al. The N501Y mutation in
SARS-CoV-2 spike leads to morbidity in obese and aged mice and is
neutralized by convalescent and post-vaccination human sera.medRxiv. 2021.
15. Corum J, Zimmer C. Coronavirus variants and mutations. The New
York Times. March 22, 2021, 2021.
16. News B. Coronavirus infection levels continue to drop in the UK. In.
5 March ed2021.
17. Candido DS, Claro IM, de Jesus JG, et al. Evolution and epidemic
spread of SARS-CoV-2 in Brazil. Science.2020;369(6508):1255-1260.
Table 1 Kinetic parameters of RBDWT and mutated
RBDs calculated by BLI